Novartis' lung cancer drug edges closer to market after FDA ...

An investigational lung cancer drug from Novartis and Incyte could be on the market midway through next year after the FDA agreed to expedite development and review in a tough to treat form

NHS funds eye gene therapy, after Novartis cuts £613,000 pri...

NICE has recommended the NHS should fund Novartis’ Luxturna for a rare eye disorder, after the company agreed a discount from the list price of more than £613,000 per patient.

Novartis strikes marketing deal for Polpharma's potential Ty...

Novartis’ biosimilars and generics arm Sandoz has struck a deal with Polpharma Biologics to market a proposed biosimilar of Biogen’s multiple sclerosis drug Tysabri (natalizumab).<

Despite trial miss, Novartis still believes in Entresto for ...

Novartis looks set to repurpose cancer drug in MS after tria...

Novartis has announced data supporting a cancer drug it acquired from GlaxoSmithKline and Genmab in a new use in multiple sclerosis, with plans for regulatory filings later this year.

Weekly roundup: More questions for Novartis in Zolgensma sca...

It’s been a tough month for Novartis, with the company facing a deepening scandal over data manipulation for its spinal muscular atrophy (SMA) gene therapy Zolgensma.